Increased Endothelial Progenitor Cell Number in Early Stage of Endometrial Cancer

Paprocka, Maria; Kiéda, Claudine; Kantor, Aneta; Bielawska‐Pohl, Aleksandra; Duś, Danuta; Czekański, Andrzej; Heimrath, Jerzy

doi:10.1097/igc.0000000000000961

Cited by 16 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, EPCs (including CECs) are increased in the peripheral blood of patients with various cancers, such as multiple myeloma [228], acute myeloid leukaemia [229, 230], nonsmall cell lung cancer (NSCLC) [231], hepatocellular carcinoma [232, 233], breast cancer [234–236], ovarian cancer [237], chronic lymphocytic leukaemia (CLL) [238], renal cell carcinoma (RCC) [239, 240], and endometrial cancer [241]. CECs have been implicated in tumour progression and aggressiveness [230, 231, 235, 237, 238, 240, 241]. Furthermore, in malignant breast carcinoma, EPCs are resistant to the cytokine TNF- α , which is responsible for inducing apoptosis [242].…”

Section: Current Prospectsmentioning

confidence: 99%

Insights into Endothelial Progenitor Cells: Origin, Classification, Potentials, and Prospects

Chopra

Hung

Kwong

et al. 2018

Stem Cells International

157

149

View full text Add to dashboard Cite

With the discovery of endothelial progenitor cells (EPCs) in the late 1990s, a paradigm shift in the concept of neoangiogenesis occurred. The identification of circulating EPCs in peripheral blood marked the beginning of a new era with enormous potential in the rapidly transforming regenerative field. Overwhelmed with the revelation, researchers across the globe focused on isolating, defining, and interpreting the role of EPCs in various physiological and pathological conditions. Consequently, controversies emerged regarding the isolation techniques and classification of EPCs. Nevertheless, the potential of using EPCs in tissue engineering as an angiogenic source has been extensively explored. Concomitantly, the impact of EPCs on various diseases, such as diabetes, cancer, and cardiovascular diseases, has been studied. Within the limitations of the current knowledge, this review attempts to delineate the concept of EPCs in a sequential manner from the speculative history to a definitive presence (origin, sources of EPCs, isolation, and identification) and significance of these EPCs. Additionally, this review is aimed at serving as a guide for investigators, identifying potential research gaps, and summarizing our current and future prospects regarding EPCs.

show abstract

Section: Current Prospectsmentioning

confidence: 99%

Insights into Endothelial Progenitor Cells: Origin, Classification, Potentials, and Prospects

Chopra

Hung

Kwong

et al. 2018

Stem Cells International

157

149

View full text Add to dashboard Cite

show abstract

“…Besides their role in cardiovascular diseases, circulating endothelial cells (CEC) are considered a biomarker for different neoplasms as they play a relevant role in tumour angiogenesis, which is essential for invasive tumour growth and metastasis [43]. Endothelial progenitor cell numbers (CD34, VEGFR2/KDR) in the peripheral blood of women with early endometrial carcinoma were significantly augmented compared with those of healthy control women, while circulating endothelial cell numbers (CD31, CD45) were similar in both groups [35]. By contrast, no prognostic significance or association with clinicopathological features have been demonstrated for the presence of disseminated tumour cells (DTC) in the bone marrow of endometrial carcinoma patients [44,45].…”

Section: Liquid Biopsy In Endometrial Cancermentioning

confidence: 99%

Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology

Muinelo‐Romay

Casas-Arozamena

Abal

2018

IJMS

View full text Add to dashboard Cite

The identification of new molecular targets and biomarkers associated with high risk of recurrence and response to therapy represents one of the main clinical challenges in the management of advanced disease in endometrial cancer. In this sense, the field of liquid biopsy has emerged as a great revolution in oncology and is considered “the way” to reach personalised medicine. In this review, we discuss the promising but already relatively limited advances of liquid biopsy in endometrial cancer compared to other types of tumours like breast, colorectal or prostate cancer. We present recent data analysing circulating tumour material in minimally-invasive blood samples, but also in alternative forms of liquid biopsy like uterine aspirates. Proteomic and genomic studies focused on liquid-based uterine samples are resulting not only in optimal diagnostic tools but also in reliable approaches to address tumour heterogeneity. Likewise, circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) represent an opportunity for the correct stratification of patients, for the assessment of early recurrent disease or for the real-time monitoring of therapy responses. Appropriately designed studies and implementation in clinical trials will determine the value of liquid biopsy for precision oncology in endometrial cancer.

show abstract

“…A comparison of anti‐CD34 and anti‐CD133 antibody‐coated stents found that the latter were more effective at capturing EPCs and achieved coating with an EPC layer in vitro . No significant difference in neointima formation and endothelialization was observed between the CD133 antibody‐coated stent and BMS in vivo , however, which may be due to the very low number of EPCs present in the circulatory system …”

Section: Introductionmentioning

confidence: 99%

“…13 No significant difference in neointima formation and endothelialization was observed between the CD133 antibody-coated stent and BMS in vivo, however, 14,15 which may be due to the very low number of EPCs present in the circulatory system. 16 Endothelialization of implanted stents can be achieved not only by circulating EPCs but also by ECs from the neighboring, intact endothelium and by circulating endothelial cells (cECs). We therefore targeted vascular endothelial growth factor receptor-2 (VEGFR2) for cell binding in this work as VEGFR2 is expressed on the surfaces of ECs, cECs, and EPCs.…”

Section: Introductionmentioning

confidence: 99%

“…We therefore targeted vascular endothelial growth factor receptor‐2 (VEGFR2) for cell binding in this work as VEGFR2 is expressed on the surfaces of ECs, cECs, and EPCs . While relative binding of the three cell types will be affected by factors such as the occurrence of cECs in human blood at approximately 20 times higher levels than EPCs, the proximity of stent‐neighboring ECs and relative expression levels of VEGFR2 in the three cell types, the approach is designed to maximize binding of all EC populations and thereby enhance stent endothelialization. Furthermore, we utilized recombinant antibody technology to generate human antibody fragments (single chain fragment variable, scFv;) against VEGFR2.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Functionalization with a VEGFR2‐binding antibody fragment leads to enhanced endothelialization of a cardiovascular stent in vitro and in vivo

et al. 2019

Self Cite

View full text Add to dashboard Cite

Rapid endothelialization of cardiovascular stents is critical to prevent major clinical complications such as restenosis. Reconstruction of the native endothelium on the stent surface can be achieved by the capture of endothelial progenitor cells (EPCs) or neighboring endothelial cells (ECs) in vivo. In this study, stainless steel cardiovascular stents were functionalized with recombinant scFv antibody fragments specific for vascular endothelial growth factor receptor‐2 (VEGFR2) that is expressed on EPCs and ECs. Anti‐VEGFR2 scFvs were expressed in glycosylated form in Escherichia coli and covalently attached to amine‐functionalized, titania‐coated steel disks and stents. ScFv‐coated surfaces exhibited no detectable cytotoxicity to human ECs or erythrocytes in vitro and bound 15 times more VEGFR2‐positive human umbilical vein ECs than controls after as little as 3 min. Porcine coronary arteries were successfully stented with scFv‐coated stents with no adverse clinical events after 30 days. Endovascular imaging and histology revealed coverage of the anti‐VEGFR2 scFv‐coated stent with a cell layer after 5 days and the presence of a neointima layer with a minimum thickness of 80 μm after 30 days. Biofunctionalization of cardiovascular stents with endothelial cell‐capturing antibody fragments in this manner offers promise in accelerating stent endothelialization in vivo. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 108B:213–224, 2020.

show abstract

Increased Endothelial Progenitor Cell Number in Early Stage of Endometrial Cancer

Abstract: These results strongly suggest new vessel formation from recruited endothelial precursors as being involved mainly at the early stages of tumor progression.

Cited by 16 publications

References 42 publications

Insights into Endothelial Progenitor Cells: Origin, Classification, Potentials, and Prospects

Insights into Endothelial Progenitor Cells: Origin, Classification, Potentials, and Prospects

Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology

Functionalization with a VEGFR2‐binding antibody fragment leads to enhanced endothelialization of a cardiovascular stent in vitro and in vivo

Contact Info

Product

Resources

About